Challenges and opportunities in designing clinical trials for neuromyelitis optica
Brian G. Weinshenker(Mayo Clinic in Arizona), Michael R. Yeaman(UCLA Medical Center), Jacinta M. Behne(Guthy-Jackson Charitable Foundation), Gerard Barron, Dean M. Wingerchuk(WinnMed), de Sèze(Hôpital d'Hautepierre), Angela T. Melia(Chugai Pharma (United States)), Bruce Cree(University of California, San Francisco), Susan VanMeter(GlaxoSmithKline (Netherlands)), Pablo Villoslada(Hospital Del Mar), Volker Knappertz(Tris Pharma (United States)), Maria Pia Sormani(University of Genoa), Warren W. Wasiewski(Tris Pharma (United States)), Armando Flor, Kazuo Fujihara(Tohoku University), Katja Van Herle(Cedars-Sinai Medical Center), Terry J. Smith(University of Michigan), Sayumi Higashi(Chugai Pharma (United States)), Omar Khan(Ayub Medical College), Michael Levy(Mass General Brigham), Jacqueline Palace(John Radcliffe Hospital), Marc K. Walton(Center for Drug Evaluation and Research), William L. Holt(Pharmaceutical Product Development (India)), Benjamin Greenberg(Centre Hospitalier Universitaire de Martinique), Peter Chin(University of British Columbia), Jeffery L. Bennett(Tris Pharma (United States))
Cited by 46
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k